T-DXd Wins FDA Priority Review
FDA Grants Priority Review to T-DXd in HER2+ Early Breast Cancer
| Read More |
FDA Issues CRL for Retifanlimab/Chemotherapy in Metastatic NSCLC
| Read More |
Videos
 Why is the Incidence of Colorectal Cancer Rising in Young Patients?
|
 Dismantling Barriers to Early Adoption of Bispecifics in Multiple Myeloma
|
Trending
 Gedatolisib Combinations Improve PFS in Advanced Breast Cancer
|
 Tazemetostat Withdrawn From Follicular Lymphoma, Sarcoma Markets
|